Atai Beckley N.V. (ATAI)
NASDAQ:ATAI
Top Page
Atai Beckley N.V.
(NASDAQ:ATAI)
Select Model
Select Model
Rating:46Neutral
Price Target:
$3.50
▲(4.48% Upside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by weak financial performance—small and volatile revenue against very large losses and ongoing cash burn—despite a comparatively manageable, low-leverage balance sheet. Technicals also detract, with the stock trading below key moving averages and bearish momentum indicators. Valuation is neutral-to-slightly supportive only in the sense that the negative P/E reflects losses and provides limited valuation clarity, with no dividend yield support.
Positive Factors
Clinical advancement & FDA alignment (BPL-003)
Constructive End-of-Phase 2 feedback and Breakthrough Therapy status materially reduce regulatory uncertainty for BPL-003. FDA alignment and a two-trial pivotal design create a clear development path, de-risking the lead asset and supporting long-term commercial planning and market entry timing.
Negative Factors
Consistent heavy cash burn
Persistent negative operating and free cash flow indicate the business consumes substantial capital to advance trials. Even with current cash, ongoing burn creates dependency on external funding over the medium term; this constrains optionality and may force financings or program prioritization if spend fails to moderate.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical advancement & FDA alignment (BPL-003)
Constructive End-of-Phase 2 feedback and Breakthrough Therapy status materially reduce regulatory uncertainty for BPL-003. FDA alignment and a two-trial pivotal design create a clear development path, de-risking the lead asset and supporting long-term commercial planning and market entry timing.
Read all positive factors
Atai Beckley N.V. (ATAI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.22B
Dividend YieldN/A
Average Volume (3M)5.30M
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees54
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding364,745,970
10 Day Avg. Volume5,439,805
30 Day Avg. Volume5,298,268
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.18
Price to Sales (P/S)226.59
P/FCF Ratio-8.95
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue136.49
Enterprise Value/Gross Profit181.38
Enterprise Value/Ebitda-4.94
Forecast
1Y Price Target
$14.10Price Target Upside320.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$466.67K
Atai Beckley N.V. Business Overview & Revenue Model
Company Description
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headqu...
How the Company Makes Money
null...
Atai Beckley N.V. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.09M | 308.00K | 314.00K | 233.00K | 20.38M |
| Gross Profit | 3.08M | 308.00K | 314.00K | 233.00K | 20.38M |
| EBITDA | -113.05M | -144.81M | -36.31M | -134.09M | -120.28M |
| Net Income | -660.05M | -149.27M | -40.22M | -152.38M | -167.81M |
Balance Sheet | |||||
| Total Assets | 310.54M | 159.39M | 293.48M | 305.44M | 414.17M |
| Cash, Cash Equivalents and Short-Term Investments | 256.04M | 62.33M | 179.26M | 273.11M | 362.27M |
| Total Debt | 2.07M | 24.71M | 19.14M | 15.34M | 743.00K |
| Total Liabilities | 88.54M | 42.83M | 49.16M | 39.67M | 28.21M |
| Stockholders Equity | 221.87M | 116.30M | 242.96M | 260.74M | 376.91M |
Cash Flow | |||||
| Free Cash Flow | -103.58M | -82.53M | -84.71M | -105.49M | -64.37M |
| Operating Cash Flow | -102.67M | -82.44M | -84.12M | -104.47M | -63.25M |
| Investing Cash Flow | -109.13M | 59.17M | -53.30M | -86.85M | -81.28M |
| Financing Cash Flow | 269.48M | 5.37M | -8.36M | 20.79M | 409.86M |
Atai Beckley N.V. Technical Analysis
Negative
3.35
Price Trends
3.76
Negative
3.94
Negative
4.07
Negative
Market Momentum
-0.11
Positive
40.18
Neutral
36.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATAI, the sentiment is Negative. The current price of 3.35 is below the 20-day moving average (MA) of 3.64, below the 50-day MA of 3.76, and below the 200-day MA of 4.07, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 40.18 is Neutral, neither overbought nor oversold. The STOCH value of 36.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATAI.
Atai Beckley N.V. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $8.08B | -21.87 | -58.74% | ― | 364.98% | -25.33% | |
57 Neutral | $1.97B | -5.95 | -399.10% | ― | -32.79% | 36.87% | |
57 Neutral | $1.21B | -5.55 | -38.79% | ― | ― | 4.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.20B | -14.03 | -84.99% | ― | 103.75% | 33.84% | |
46 Neutral | $1.22B | -1.40 | -389.74% | ― | ― | ― |
* Healthcare Sector Average
ATAI
Atai Beckley N.V.
3.35
1.99
146.32%
NKTR
Nektar Therapeutics
68.66
58.46
573.14%
WVE
Wave Life Sciences
6.37
-1.71
-21.23%
ORIC
Oric Pharmaceuticals
12.06
6.48
116.13%
PRAX
Praxis Precision Medicines
290.10
252.23
666.04%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.